Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Paternostro

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
ESMO Open|June 17, 2021
Cancer and hepatic steatosisR Paternostro, W Sieghart, M Trauner, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2018
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response studyR Schwarzer, D Kivaranovic, R Paternostro, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2017
Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertensionR Schwarzer, D Kivaranovic, M Mandorfer, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2018
Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertensionM Mandorfer, B Scheiner, A F Stättermayer, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2018
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severityM Mandorfer, P Schwabl, R Paternostro, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
ESMO Open|June 17, 2021
Cancer and hepatic steatosisR Paternostro, W Sieghart, M Trauner, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2018
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response studyR Schwarzer, D Kivaranovic, R Paternostro, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2017
Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertensionR Schwarzer, D Kivaranovic, M Mandorfer, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2018
Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertensionM Mandorfer, B Scheiner, A F Stättermayer, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2018
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severityM Mandorfer, P Schwabl, R Paternostro, et al.
Pageof 1